for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Rocket Pharmaceuticals Inc

RCKT.OQ

Latest Trade

13.05USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

10.75

 - 

25.85

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.05
Open
--
Volume
--
3M AVG Volume
7.24
Today's High
--
Today's Low
--
52 Week High
25.85
52 Week Low
10.75
Shares Out (MIL)
50.35
Market Cap (MIL)
666.11
Forward P/E
-7.32
Dividend (Yield %)
--

Latest Developments

More

Rocket Pharmaceuticals Reports Second Quarter 2019 Financial Results And Operational Highlights

Rocket Pharmaceuticals Inc Files For $350 Million Mixed Shelf Offering - SEC Filing

Rocket Pharmaceuticals Prices Public Offering

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.

Industry

Biotechnology & Drugs

Contact Info

350 5th Ave Ste 7530

+1.646.4409100

http://www.inotekpharma.com/

Executive Leadership

Roderick Wong

Chairman of the Board

Gaurav Shah

President, Chief Executive Officer, Director

John Militello

Principal Financial Officer, Principal Accounting Officer, Controller

Kinnari Patel

Chief Operating Officer and Head of Development

Jonathan Schwartz

Chief Medical Officer

Key Stats

1.38 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-6.400

2017

-4.360

2018

-1.890

2019(E)

-1.808
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.68
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
17.38
LT Debt To Equity (MRQ)
17.38
Return on Investment (TTM)
-33.21
Return on Equity (TTM)
-31.59

Latest News

BRIEF-Rocket Pharmaceuticals Presents Updated Data From Phase 1/2 Gene Therapy Trial Of Rp-L102

* ROCKET PHARMACEUTICALS PRESENTS UPDATED DATA FROM PHASE 1/2 GENE THERAPY TRIAL OF RP-L102 IN PATIENTS WITH FANCONI ANEMIA AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) ANNUAL MEETING

BRIEF-Rocket Pharmaceuticals Announces Strategic Research Collaboration

* ROCKET PHARMACEUTICALS ANNOUNCES STRATEGIC RESEARCH COLLABORATION

BRIEF-Rocket Pharma Appoints Former FDA Staffer As VP Of Regulatory Policy And Patient Advocacy

* ROCKET PHARMACEUTICALS APPOINTS GAYATRI R. RAO, M.D., J.D., FORMER U.S. FOOD AND DRUG ADMINISTRATION DIRECTOR OF THE OFFICE OF ORPHAN PRODUCTS DEVELOPMENT, AS VICE PRESIDENT, REGULATORY POLICY AND PATIENT ADVOCACY Source text for Eikon: Further company coverage:

BRIEF-Rocket Pharmaceuticals Reports Q1 Loss Per Share Of $0.42

* ROCKET PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Rocket-control glitch delays launch of NASA's planet-hunting satellite

An 11th-hour technical glitch prompted SpaceX to postpone its planned launch on Monday of a new NASA space telescope designed to detect worlds beyond our solar system, delaying for at least 48 hours a quest to expand astronomers' known inventory of so-called exoplanets.

BRIEF-Rocket Pharmaceuticals Reports Full-Year 2017 Results

* ROCKET PHARMACEUTICALS REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BRIEF-Rocket Pharmaceuticals Prices Public Offering Of Common Stock

* ROCKET PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Rocket Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* ROCKET PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Tang Capital Partners Reports 8.1 Pct Passive Stake In Rocket Pharmaceuticals - SEC Filing

* TANG CAPITAL PARTNERS REPORTS 8.1 PCT PASSIVE STAKE IN ROCKET PHARMACEUTICALS INC AS OF JAN 4 - SEC FILING Source text: (http://bit.ly/2ra05Is) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up